al-Khadra A S, Konstam M A, Salem D N
Department of Medicine, New England Medical Center Hospitals, Boston, MA 02111.
Compr Ther. 1994;20(4):257-62.
Results of the SOLVD prevention trial and of the SAVE trial indicate that long-term treatment with ACE inhibitors in asymptomatic patients with LV systolic dysfunction prevents the progression to overt CHF and reduces hospitalizations for CHF. ACE inhibitors have been shown to reduce mortality in at least some subsets of asymptomatic patients with LV systolic dysfunction, notably those with recent myocardial infarction.
